Is tamoxifene porphyrinogenic?;Je tamoxifen porfyrinogenní?

Casopis Lekaru Ceskych

Volumn 144, Issue 4, 2005, Pages 262-264

  Malina, L ^a,c   Mottl, V ^b   Michalikova H ^b  

^a IPVZ   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c NONE   (Czech Republic)

Author keywords

Breast carcinoma; Cytostatic drugs; Estrogenic hormons; PCT; Porphyria cutanea tarda; Tamoxifene

Indexed keywords

CHOLESTEROL; COPROPORPHYRIN; FERRITIN; HEPATITIS C ANTIBODY; IRON; SUGAR; TAMOXIFEN; UROPORPHYRIN;

ARTICLE; BLOOD CELL COUNT; BREAST CANCER; CANCER CHEMOTHERAPY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; LIVER FUNCTION TEST; LIVER TOXICITY; PHLEBOTOMY; PORPHYRIA CUTANEA TARDA; URINALYSIS; URINARY EXCRETION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG ERUPTIONS; FEMALE; HUMANS; MIDDLE AGED; PORPHYRIA CUTANEA TARDA; PORPHYRINS; TAMOXIFEN;

EID: 18044391484     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rizzardini, M., Ferraroli, A., Del Fiume, D. et al.: Cyclophosphamide - impaired regulation of hepatic heme metabolism. Experimentia, 1984, 40, s. 1390-1393.
2. Wainstok de Calmanovici, R., San Martin de Viale, L. C.: Effect of some antineoplastics on metabolic heme pathway. Int. J. Biochem., 1988, 20, s. 1015-1020.
3. Manzione, N. C., Wolkoff, A. W., Sassa, S.: Development of porphyria cutanea tarda after treatment with cyclophosphamide. Gastroenterology, 1988, 95, s. 1119-1122.
4. Malina, L., Michalíková, H., Hussarová, L.: Porphyria cutanea tarda po protinádorových lécích. Čas. Lék. čes., 1999, 138, s. 536-538.
5. Elder, G. H.: Porphyria cutanea tarda. Semin. Liver Dis., 1998, 18, s. 67-75.
6. Bonkovsky, H. L., Sinclair, P. R., Lambrecht, R. W. et al.: Role of cytochrome P450 in porphyria caused by halogenated aromatic compounds. Ann. NY Acad. Sci., 1976, 514, s. 96-112.
7. Kushner, J. P., Barbuto, A. J., Lee, G. R.: An inherited enzymatic defect in porphyria cutanea tarda. Decreased uroporphyrinogen decarboxylase activity. J. Clin. Invest., 1976, 58, s. 1089-1097.
8. McManus, J. F., Begley, C. G., Sassa, S. et al.: Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with porphyria cutanea tarda. Blood, 1996, 88, s. 3589-3600.
9. Elder, G. H., Lee, G. B., Tovey, J. A.: Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda. N. Engl. J. Med., 1968, 299, s. 241-247.
10. Fletcher, L. M., Halliday, J. W., Powell, L. W.: Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin nad transferrin. J Gastroenerol. Hepatol., 1999, 14, s. 202-214.
11. Fargion, S., Piperno, A., Cappellini, M. D. et al.: Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology, 1992, 16, s. 1322-1326.
12. Roberts, A. G., Whatley, S. D., Morgan, N. N. et al.: Increased frequency of the haemosiderosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet, 1997, 349, s. 321-312.
13. Granick, S.: The induction in vitro of the synthesis of delta- aminolevulinic acid synthetase in chemical porphyria: a response to certain drugs, sex hormones, and foreign chemicals. J. Biol. Chem. 1966, 241, s. 1359-1375.
14. Roenigk, H. H., Jr., Gottlob, M. E.: Estrogen-induced porphyria cutanea tarda. Report of three cases. Arch. Dermatol., 1970, 102, s. 260-266.
15. Fex, G., Adielsson, G.: Oestrogen like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol., 1981, 97, s. 109-113.
16. Louis, D. B., Claude, B., Come, R.: Severe lipemia induced by tamoxifen. Cancer, 1986, 57, s. 2123-2126.
17. 14C] tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem. Pharmacol. 1995, 49, s. 1035-1042.
18. Ogawa, Y., Murata, Y., Nishioka, A. et al.: Tamoxifen-induced fatty liver in patients with breast cancer. Lancet, 1998, 351, s. 725.
19. Diehl, A. M., Goodman, Z., Ishak, K. G.: Alcohol-like disease in nonalcoholics. Gastroenterelogy, 1988, 95, s. 1056-1062.
20. Bulaj, Z. J., Phillips, J. D., Ajioka, R. S. et al.: Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood, 2000, 95, s. 1565-1571.
21. Agarwal, R., Peters, T. J., Coombes, R. C. et al.: Tamoxifen -related porphyria cutanea tarda. Medical Oncology, 2002, 19, s. 121-123.
22. Pierach, C. A., Bender, G. P.: Tamoxifen and porphyria. Millenium Meeting on Porphyrins and Porphyria, 2000, s. 33.
23. Cochón, A., Aldonatti, C., San Martín de Viale, L. C. et al.: Evaluation of the porphyrinogenic risk of antineoplastics. J. Appl. Toxicol., 1997, 17, s. 171-177.